- Conditions
- Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
- Interventions
- Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
- Procedure · Device
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2016
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- NeuVax vaccine, Trastuzumab, GM-CSF
- Biological · Drug
- Lead sponsor
- Cancer Insight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 24
- States / cities
- Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
- Interventions
- Inebilizumab, Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Hialeah, Florida + 13 more
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer
- Interventions
- RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more
- Conditions
- Metastatic Cancer
- Interventions
- efaproxiral, radiation therapy
- Drug · Radiation
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
- Conditions
- X Linked Hypohidrotic Ectodermal Dysplasia
- Interventions
- Not listed
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Secukinumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- Avondale, Arizona • Peoria, Arizona • Westlake Village, California + 9 more
- Conditions
- Peripheral Nerve Injuries
- Interventions
- Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft, Nerve Tube Conduit, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization
- Other · Device · Procedure
- Lead sponsor
- Axogen Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2028
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Orange, California • San Francisco, California + 33 more
- Conditions
- Lung Cancer
- Interventions
- PET/CT Scan
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- VK2809, Placebos
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 68
- States / cities
- Madison, Alabama • Glendale, Arizona • Tucson, Arizona + 57 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 19
- States / cities
- La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Life Length SL
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 509 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Hialeah, Florida • Houston, Texas
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 35,895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 473
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more
- Conditions
- Breast Cancer
- Interventions
- SRG-514
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Savannah, Georgia • Indianapolis, Indiana • Rochester, Minnesota + 5 more
- Conditions
- Smoking, Tobacco
- Interventions
- P2613422, P2611222, P2615522, P2615122, P2615422
- Other
- Lead sponsor
- RAI Services Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 1,280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Maitland, Florida • Atlanta, Georgia • St Louis, Missouri + 4 more
- Conditions
- Stroke
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 7,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
- Conditions
- GIST and CML
- Interventions
- imatinib mesylate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
- Interventions
- OPC-34712 + ADT, Placebo + ADT
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Costa Mesa, California • Glendale, California + 49 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 51
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
- Conditions
- Myelodysplastic Syndrome, Myelodysplastic Syndromes
- Interventions
- GSK2879552, Azacitidine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Augusta, Georgia • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Solid Tumor
- Interventions
- ASTX295
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 8 more
- Conditions
- Forehead Rhytides, Forehead Wrinkles
- Interventions
- Botulinum toxin type A, 2.5% lidocaine/2.5% prilocaine, petrolatum ointment
- Drug · Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma
- Interventions
- irinotecan hydrochloride, temozolomide
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 96 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- VitalScan Magnetocardiograph
- Device
- Lead sponsor
- Creavo Medical Technologies Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Winston-Salem, North Carolina • Cincinnati, Ohio + 2 more